Ontology highlight
ABSTRACT:
SUBMITTER: Province MA
PROVIDER: S-EPMC3904554 | biostudies-literature | 2014 Feb
REPOSITORIES: biostudies-literature
Province M A MA Goetz M P MP Brauch H H Flockhart D A DA Hebert J M JM Whaley R R Suman V J VJ Schroth W W Winter S S Zembutsu H H Mushiroda T T Newman W G WG Lee M-T M MT Ambrosone C B CB Beckmann M W MW Choi J-Y JY Dieudonné A-S AS Fasching P A PA Ferraldeschi R R Gong L L Haschke-Becher E E Howell A A Jordan L B LB Hamann U U Kiyotani K K Krippl P P Lambrechts D D Latif A A Langsenlehner U U Lorizio W W Neven P P Nguyen A T AT Park B-W BW Purdie C A CA Quinlan P P Renner W W Schmidt M M Schwab M M Shin J-G JG Stingl J C JC Wegman P P Wingren S S Wu A H B AH Ziv E E Zirpoli G G Thompson A M AM Jordan V C VC Nakamura Y Y Altman R B RB Ames M M MM Weinshilboum R M RM Eichelbaum M M Ingle J N JN Klein T E TE
Clinical pharmacology and therapeutics 20130923 2
The International Tamoxifen Pharmacogenomics Consortium was established to address the controversy regarding cytochrome P450 2D6 (CYP2D6) status and clinical outcomes in tamoxifen therapy. We performed a meta-analysis on data from 4,973 tamoxifen-treated patients (12 globally distributed sites). Using strict eligibility requirements (postmenopausal women with estrogen receptor-positive breast cancer, receiving 20 mg/day tamoxifen for 5 years, criterion 1); CYP2D6 poor metabolizer status was asso ...[more]